6月3日，据CDE官网消息，杭州中美华东制药有限公司联合申请药品“CMCY2501片”，获得临床试验默示许可，受理号CXHL2500314。
公示信息显示，药品“CMCY2501片”适应症：用于冠心病患者PCI术后的动脉粥样硬化血栓形成事件的二级预防，与P2Y12受体抑制剂合用。
杭州中美华东制药有限公司，成立于1992年，位于杭州市，是一家以从事医药制造业为主的企业。企业注册资本87230.813万人民币，实缴资本87230.813万人民币。
通过天眼查大数据分析，杭州中美华东制药有限公司共对外投资了18家企业，参与招投标项目5000次，知识产权方面有商标信息340条，专利信息391条，此外企业还拥有行政许可890个。
主要股东信息显示，杭州中美华东制药有限公司由华东医药股份有限公司持股100%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.